Ginkgo Biloba

Last Updated: September 28 2022

Ginkgo biloba is the most commonly ingested herb for brain health. While it may boost cognition in older populations, this effect is not very reliable or generalizable.

Ginkgo Biloba is most often used for

What is Ginkgo biloba?

Ginkgo biloba (ginkgo) is a tree whose leaves are often used as a dietary supplement for the purposes of cognitive improvement. These leaves contain a variety of potentially bioactive compounds, including several types of flavonoids and terpenoids.

What are Ginkgo biloba’s main benefits?#

Ginkgo biloba seems to improve aspects of cognitive function in people with dementia.[298] There is also preliminary evidence that ginkgo can improve cognitive function in healthy middle-aged people[299] and healthy older people.[300] It is unclear whether ginkgo can improve cognitive function in healthy younger people, as most studies on this population have reported no clear benefit.[301]

What are Ginkgo biloba’s main drawbacks?

No significant safety concerns associated with Ginkgo biloba leaf extract have been clearly identified in human clinical trials. Although case studies have indicated that ginkgo might increase bleeding risk,[302] a meta-analysis of 18 randomized controlled trials found no higher risk of bleeding in participants who took standardized extracts.[303] There have been rare reports of seizures among people with epilepsy who supplemented with ginkgo, perhaps due to stimulation of the enzymatic breakdown of anticonvulsant medication.[302] Finally, experiments in rodents have suggested that ginkgo extract may be carcinogenic.[304]

How does Ginkgo biloba work?

There is no well-established mechanism to explain how Gingko biloba improves cognitive function, but a few possibilities have been proposed. Among these are improved blood flow to the brain,[305] reduced oxidative stress,[306] and inhibition of the neurotoxic effects of amyloid beta.[306]

What else is Ginkgo Biloba known as?
Note that Ginkgo Biloba is also known as:
  • Tanakan
  • Tebonin
  • Rökan
  • Maidenhair
  • gingko
Ginkgo Biloba should not be confused with:
Dosage information

For cognitive enhancement, take 120-240mg, one to four hours before performance. To alleviate cognitive decline in older adults, take 40-120mg, three times a day. The supplement form of Ginkgo biloba is also called EGb-761 extract. It should be a 50:1 concentrated extract. Ginkgo biloba should be taken with meals.

Join our supplement information course

Examine Database: Ginkgo Biloba
What works and what doesn't?

Unlock the full potential of Examine

Get started

Don't miss out on the latest research

Research Breakdown

1.^DeFeudis FVA brief history of EGb 761 and its therapeutic usesPharmacopsychiatry.(2003 Jun)
3.^Curtis-Prior P, Vere D, Fray PTherapeutic value of Ginkgo biloba in reducing symptoms of decline in mental functionJ Pharm Pharmacol.(1999 May)
5.^Ekman L, Fransson D, Claeson P, Johansson MDevelopment of an alternative method for determination of terpene lactones in ginkgo dry extractPharmeur Bio Sci Notes.(2009 Oct)
6.^[No authors listedEGb 761: ginkgo biloba extract, GinkorDrugs R D.(2003)
8.^Vitolo O, Gong B, Cao Z, Ishii H, Jaracz S, Nakanishi K, Arancio O, Dzyuba SV, Lefort R, Shelanski MProtection against beta-amyloid induced abnormal synaptic function and cell death by Ginkgolide JNeurobiol Aging.(2009 Feb)
10.^Scholtyssek H, Damerau W, Wessel R, Schimke IAntioxidative activity of ginkgolides against superoxide in an aprotic environmentChem Biol Interact.(1997 Oct 24)
11.^Liao HJ, Zheng YF, Li HY, Peng GPTwo new ginkgolides from the leaves of Ginkgo bilobaPlanta Med.(2011 Nov)
15.^Qaâdan F, Nahrstedt A, Schmidt M, Mansoor KPolyphenols from Ginkgo bilobaSci Pharm.(2010)
17.^Sloley BD, Urichuk LJ, Morley P, Durkin J, Shan JJ, Pang PK, Coutts RTIdentification of kaempferol as a monoamine oxidase inhibitor and potential Neuroprotectant in extracts of Ginkgo biloba leavesJ Pharm Pharmacol.(2000 Apr)
18.^Briançon-Scheid F, Lobstein-Guth A, Anton RHPLC Separation and Quantitative Determination of Biflavones in Leaves from Ginkgo bilobaPlanta Med.(1983 Dec)
19.^Hyun SK, Kang SS, Son KH, Chung HY, Choi JSBiflavone glucosides from Ginkgo biloba yellow leavesChem Pharm Bull (Tokyo).(2005 Sep)
22.^Hauns B, Häring B, Köhler S, Mross K, Robben-Bathe P, Unger CPhase II study with 5-fluorouracil and ginkgo biloba extract (GBE 761 ONC) in patients with pancreatic cancerArzneimittelforschung.(1999 Dec)
23.^Meston CM, Rellini AH, Telch MJShort- and long-term effects of Ginkgo biloba extract on sexual dysfunction in womenArch Sex Behav.(2008 Aug)
24.^Biber APharmacokinetics of Ginkgo biloba extractsPharmacopsychiatry.(2003 Jun)
26.^Birks J, Grimley Evans JGinkgo biloba for cognitive impairment and dementiaCochrane Database Syst Rev.(2009 Jan 21)
27.^Diamond BJ, Shiflett SC, Feiwel N, Matheis RJ, Noskin O, Richards JA, Schoenberger NEGinkgo biloba extract: mechanisms and clinical indicationsArch Phys Med Rehabil.(2000 May)
29.^Woelkart K, Feizlmayr E, Dittrich P, Beubler E, Pinl F, Suter A, Bauer RPharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humansPhytother Res.(2010 Mar)
33.^Lau AJ, Yang G, Rajaraman G, Baucom CC, Chang TKHuman pregnane X receptor agonism by Ginkgo biloba extract: assessment of the role of individual ginkgolidesJ Pharmacol Exp Ther.(2010 Dec)
34.^Deng Y, Bi HC, Zhao LZ, He F, Liu YQ, Yu JJ, Ou ZM, Ding L, Chen X, Huang ZY, Huang M, Zhou SFInduction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in ratsXenobiotica.(2008 May)
35.^Blonk M, Colbers A, Poirters A, Schouwenberg B, Burger DEffect of ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteersAntimicrob Agents Chemother.(2012 Oct)
36.^Wiegman DJ, Brinkman K, Franssen EJInteraction of Ginkgo biloba with efavirenzAIDS.(2009 Jun 1)
37.^Naccarato M, Yoong D, Gough KA Potential Drug-Herbal Interaction between Ginkgo biloba and EfavirenzJ Int Assoc Physicians AIDS Care (Chic).(2012 Mar-Apr)
38.^Guo CX, Pei Q, Yin JY, Peng XD, Zhou BT, Zhao YC, Wu LX, Meng XG, Wang G, Li Q, Ouyang DS, Liu ZQ, Zhang W, Zhou HHEffects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indicesXenobiotica.(2012 Aug)
42.^Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJEffect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjectsBr J Clin Pharmacol.(2005 Apr)
43.^Janssens D, Remacle J, Drieu K, Michiels CProtection of mitochondrial respiration activity by bilobalideBiochem Pharmacol.(1999 Jul 1)
44.^Janssens D, Michiels C, Delaive E, Eliaers F, Drieu K, Remacle JProtection of hypoxia-induced ATP decrease in endothelial cells by ginkgo biloba extract and bilobalideBiochem Pharmacol.(1995 Sep 28)
45.^Du G, Willet K, Mouithys-Mickalad A, Sluse-Goffart CM, Droy-Lefaix MT, Sluse FEEGb 761 protects liver mitochondria against injury induced by in vitro anoxia/reoxygenationFree Radic Biol Med.(1999 Sep)
46.^Eckert A, Keil U, Kressmann S, Schindowski K, Leutner S, Leutz S, Müller WEEffects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stressPharmacopsychiatry.(2003 Jun)
47.^Janssens D, Delaive E, Remacle J, Michiels CProtection by bilobalide of the ischaemia-induced alterations of the mitochondrial respiratory activityFundam Clin Pharmacol.(2000 May-Jun)
48.^Janssens D, Delaive E, Houbion A, Eliaers F, Remacle J, Michiels CEffect of venotropic drugs on the respiratory activity of isolated mitochondria and in endothelial cellsBr J Pharmacol.(2000 Aug)
49.^Sastre J, Millán A, García de la Asunción J, Plá R, Juan G, Pallardó, O'Connor E, Martin JA, Droy-Lefaix MT, Viña JA Ginkgo biloba extract (EGb 761) prevents mitochondrial aging by protecting against oxidative stressFree Radic Biol Med.(1998 Jan 15)
53.^White HL, Scates PW, Cooper BRExtracts of Ginkgo biloba leaves inhibit monoamine oxidaseLife Sci.(1996)
57.^Watanabe CM, Wolffram S, Ader P, Rimbach G, Packer L, Maguire JJ, Schultz PG, Gohil KThe in vivo neuromodulatory effects of the herbal medicine ginkgo bilobaProc Natl Acad Sci U S A.(2001 Jun 5)
58.^Augustin S, Rimbach G, Augustin K, Cermak R, Wolffram SGene Regulatory Effects of Ginkgo biloba Extract and Its Flavonol and Terpenelactone Fractions in Mouse BrainJ Clin Biochem Nutr.(2009 Nov)
59.^Kuchler-Bopp S, Dietrich JB, Zaepfel M, Delaunoy JPReceptor-mediated endocytosis of transthyretin by ependymoma cellsBrain Res.(2000 Jul 7)
67.^Bolaños-Jiménez F, Manhães de Castro R, Sarhan H, Prudhomme N, Drieu K, Fillion GStress-induced 5-HT1A receptor desensitization: protective effects of Ginkgo biloba extract (EGb 761)Fundam Clin Pharmacol.(1995)
69.^Izumi J, Washizuka M, Miura N, Hiraga Y, Ikeda YHippocampal serotonin 5-HT1A receptor enhances acetylcholine release in conscious ratsJ Neurochem.(1994 May)
70.^Lummis SC5-HT(3) receptorsJ Biol Chem.(2012 Nov 23)
71.^Thompson AJ, Jarvis GE, Duke RK, Johnston GA, Lummis SCGinkgolide B and bilobalide block the pore of the 5-HT₃receptor at a location that overlaps the picrotoxin binding siteNeuropharmacology.(2011 Feb-Mar)
75.^Jahanshahi M, Nickmahzar EG, Babakordi FThe effect of Ginkgo biloba extract on scopolamine-induced apoptosis in the hippocampus of ratsAnat Sci Int.(2013 Jul 5)
78.^Burns A, O'Brien J; BAP Dementia Consensus group, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D; British Association for PsychopharmacologyClinical practice with anti-dementia drugs: a consensus statement from British Association for PsychopharmacologyJ Psychopharmacol.(2006 Nov)
79.^Huang SH, Duke RK, Chebib M, Sasaki K, Wada K, Johnston GABilobalide, a sesquiterpene trilactone from Ginkgo biloba, is an antagonist at recombinant alpha1beta2gamma2L GABA(A) receptorsEur J Pharmacol.(2003 Mar 7)
80.^Kamei C, Okumura Y, Tasaka KInfluence of histamine depletion on learning and memory recollection in ratsPsychopharmacology (Berl).(1993)
81.^Kamei C, Chung YH, Tasaka KInfluence of certain H1-blockers on the step-through active avoidance response in ratsPsychopharmacology (Berl).(1990)
82.^Schneider C, Risser D, Kirchner L, Kitzmüller E, Cairns N, Prast H, Singewald N, Lubec GSimilar deficits of central histaminergic system in patients with Down syndrome and Alzheimer diseaseNeurosci Lett.(1997 Feb 7)
83.^Higuchi M, Yanai K, Okamura N, Meguro K, Arai H, Itoh M, Iwata R, Ido T, Watanabe T, Sasaki HHistamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomographyNeuroscience.(2000)
84.^Tchantchou F, Lacor PN, Cao Z, Lao L, Hou Y, Cui C, Klein WL, Luo YStimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neuronsJ Alzheimers Dis.(2009)
85.^Pittenger C, Duman RSStress, depression, and neuroplasticity: a convergence of mechanismsNeuropsychopharmacology.(2008 Jan)
86.^Nakagawa S, Kim JE, Lee R, Malberg JE, Chen J, Steffen C, Zhang YJ, Nestler EJ, Duman RSRegulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding proteinJ Neurosci.(2002 May 1)
87.^Chen YS, Liu CJ, Cheng CY, Yao CHEffect of bilobalide on peripheral nerve regenerationBiomaterials.(2004 Feb)
88.^Bruno C, Cuppini R, Sartini S, Cecchini T, Ambrogini P, Bombardelli ERegeneration of motor nerves in bilobalide-treated ratsPlanta Med.(1993 Aug)
90.^Jin GH, Huang Z, Tan XF, Tian ML, Zhang XH, Qin JB, Xu HJ, Yew DT, Mak YTEffects of Ginkgolide on the development of NOS and AChE positive neurons in the embryonic basal forebrainCell Biol Int.(2006 Jun)
92.^Zhang XY, Zhang WF, Zhou DF, Chen da C, Xiu MH, Wu HR, Haile CN, Kosten TA, Kosten TRBrain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo bilobaBiol Psychiatry.(2012 Oct 15)
93.^Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DRThe BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal functionCell.(2003 Jan 24)
97.^Zhuang H, Pin S, Christen Y, Doré SInduction of heme oxygenase 1 by Ginkgo biloba in neuronal cultures and potential implications in ischemiaCell Mol Biol (Noisy-le-grand).(2002 Sep)
98.^Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, Khan I, Netzer WJ, Xu H, Butko PInhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761Proc Natl Acad Sci U S A.(2002 Sep 17)
99.^Sarris J, Panossian A, Schweitzer I, Stough C, Scholey AHerbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidenceEur Neuropsychopharmacol.(2011 Dec)
101.^Ward CP, Redd K, Williams BM, Caler JR, Luo Y, McCoy JGGinkgo biloba extract: cognitive enhancer or antistress bufferPharmacol Biochem Behav.(2002 Jul)
104.^Marcilhac A, Dakine N, Bourhim N, Guillaume V, Grino M, Drieu K, Oliver CEffect of chronic administration of Ginkgo biloba extract or Ginkgolide on the hypothalamic-pituitary-adrenal axis in the ratLife Sci.(1998)
106.^Rojas P, Serrano-García N, Medina-Campos ON, Pedraza-Chaverri J, Ogren SO, Rojas CAntidepressant-like effect of a Ginkgo biloba extract (EGb761) in the mouse forced swimming test: role of oxidative stressNeurochem Int.(2011 Oct)
107.^Kamkaew N, Norman Scholfield C, Ingkaninan K, Taepavarapruk N, Chootip KBacopa monnieri Increases Cerebral Blood Flow in Rat Independent of Blood PressurePhytother Res.(2012 Mar 23)
109.^Mashayekh A, Pham DL, Yousem DM, Dizon M, Barker PB, Lin DDEffects of Ginkgo biloba on cerebral blood flow assessed by quantitative MR perfusion imaging: a pilot studyNeuroradiology.(2011 Mar)
110.^Santos RF, Galduróz JC, Barbieri A, Castiglioni ML, Ytaya LY, Bueno OFCognitive performance, SPECT, and blood viscosity in elderly non-demented people using Ginkgo bilobaPharmacopsychiatry.(2003 Jul)
113.^Kuller LH, Ives DG, Fitzpatrick AL, Carlson MC, Mercado C, Lopez OL, Burke GL, Furberg CD, DeKosky ST; Ginkgo Evaluation of Memory Study InvestigatorsDoes Ginkgo biloba reduce the risk of cardiovascular eventsCirc Cardiovasc Qual Outcomes.(2010 Jan)
114.^Zeng X, Liu M, Yang Y, Li Y, Asplund KGinkgo biloba for acute ischaemic strokeCochrane Database Syst Rev.(2005 Oct 19)
115.^Kennedy DO, Scholey AB, Wesnes KAThe dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteersPsychopharmacology (Berl).(2000 Sep)
119.^Salehi B, Imani R, Mohammadi MR, Fallah J, Mohammadi M, Ghanizadeh A, Tasviechi AA, Vossoughi A, Rezazadeh SA, Akhondzadeh SGinkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trialProg Neuropsychopharmacol Biol Psychiatry.(2010 Feb 1)
121.^Lyon MR, Cline JC, Totosy de Zepetnek J, Shan JJ, Pang P, Benishin CEffect of the herbal extract combination Panax quinquefolium and Ginkgo biloba on attention-deficit hyperactivity disorder: a pilot studyJ Psychiatry Neurosci.(2001 May)
123.^Brondino N, De Silvestri A, Re S, Lanati N, Thiemann P, Verna A, Emanuele E, Politi PA Systematic Review and Meta-Analysis of Ginkgo biloba in Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day MedicineEvid Based Complement Alternat Med.(2013)
125.^Usai S, Grazzi L, Andrasik F, Bussone GAn innovative approach for migraine prevention in young age: a preliminary studyNeurol Sci.(2010 Jun)
127.^D'Andrea G, Bussone G, Allais G, Aguggia M, D'Onofrio F, Maggio M, Moschiano F, Saracco MG, Terzi MG, Petretta V, Benedetto CEfficacy of Ginkgolide B in the prophylaxis of migraine with auraNeurol Sci.(2009 May)
128.^Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux RGinkgo for memory enhancement: a randomized controlled trialJAMA.(2002 Aug 21)
129.^Elsabagh S, Hartley DE, Ali O, Williamson EM, File SEDifferential cognitive effects of Ginkgo biloba after acute and chronic treatment in healthy young volunteersPsychopharmacology (Berl).(2005 May)
130.^Stough C, Clarke J, Lloyd J, Nathan PJNeuropsychological changes after 30-day Ginkgo biloba administration in healthy participantsInt J Neuropsychopharmacol.(2001 Jun)
139.^Brautigam MR, Blommaert FA, Verleye G, Castermans J, Jansen Steur EN, Kleijnen JTreatment of age-related memory complaints with Ginkgo biloba extract: a randomized double blind placebo-controlled studyPhytomedicine.(1998 Dec)
140.^Jonker C, Geerlings MI, Schmand BAre memory complaints predictive for dementia? A review of clinical and population-based studiesInt J Geriatr Psychiatry.(2000 Nov)
141.^Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S; GuidAge Study GroupLong-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trialLancet Neurol.(2012 Oct)
142.^DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD; Ginkgo Evaluation of Memory (GEM) Study InvestigatorsGinkgo biloba for prevention of dementia: a randomized controlled trialJAMA.(2008 Nov 19)
143.^Snitz BE, O'Meara ES, Carlson MC, Arnold AM, Ives DG, Rapp SR, Saxton J, Lopez OL, Dunn LO, Sink KM, DeKosky ST; Ginkgo Evaluation of Memory (GEM) Study InvestigatorsGinkgo biloba for preventing cognitive decline in older adults: a randomized trialJAMA.(2009 Dec 23)
147.^Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AFA placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study GroupJAMA.(1997 Oct 22-29)
149.^McCarney R, Fisher P, Iliffe S, van Haselen R, Griffin M, van der Meulen J, Warner JGinkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trialInt J Geriatr Psychiatry.(2008 Dec)
156.^Murray BJ, Cowen PJ, Sharpley ALThe effect of Li 1370, extract of Ginkgo biloba, on REM sleep in humansPharmacopsychiatry.(2001 Jul)
157.^Hemmeter U, Annen B, Bischof R, Brüderlin U, Hatzinger M, Rose U, Holsboer-Trachsler EPolysomnographic effects of adjuvant ginkgo biloba therapy in patients with major depression medicated with trimipraminePharmacopsychiatry.(2001 Mar)
158.^Rao SM, Leo GJ, Bernardin L, Unverzagt FCognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and predictionNeurology.(1991 May)
159.^Amato MP, Ponziani G, Siracusa G, Sorbi SCognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 yearsArch Neurol.(2001 Oct)
160.^Lovera JF, Kim E, Heriza E, Fitzpatrick M, Hunziker J, Turner AP, Adams J, Stover T, Sangeorzan A, Sloan A, Howieson D, Wild K, Haselkorn J, Bourdette DGinkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trialNeurology.(2012 Sep 18)
161.^Yao JK, Reddy R, van Kammen DPReduced level of plasma antioxidant uric acid in schizophreniaPsychiatry Res.(1998 Jul 27)
162.^Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc NLipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorderCell Biochem Funct.(2002 Jun)
163.^Bilici M, Efe H, Köroğlu MA, Uydu HA, Bekaroğlu M, Değer OAntioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatmentsJ Affect Disord.(2001 Apr)
164.^Yao JK, Reddy R, McElhinny LG, van Kammen DPReduced status of plasma total antioxidant capacity in schizophreniaSchizophr Res.(1998 Jun 22)
168.^Remington GTardive dyskinesia: eliminated, forgotten, or overshadowedCurr Opin Psychiatry.(2007 Mar)
169.^Lohr JB, Kuczenski R, Niculescu ABOxidative mechanisms and tardive dyskinesiaCNS Drugs.(2003)
171.^Nishio T, Furukawa S, Akiguchi I, Sunohara NMedial nigral dopamine neurons have rich neurotrophin support in humansNeuroreport.(1998 Aug 24)
172.^Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JTMarkers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesiaAm J Psychiatry.(1998 Sep)
173.^Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJAnterograde transport of brain-derived neurotrophic factor and its role in the brainNature.(1997 Oct 23)
178.^Akhondzadeh S, Tajdar H, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Shabstari OL, Ghelichnia HAA double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorderChild Psychiatry Hum Dev.(2008 Sep)
179.^Hasanzadeh E, Mohammadi MR, Ghanizadeh A, Rezazadeh SA, Tabrizi M, Rezaei F, Akhondzadeh SA double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disordersChild Psychiatry Hum Dev.(2012 Oct)
182.^Ylä-Herttuala S, Palinski W, Rosenfeld ME, Steinberg D, Witztum JLLipoproteins in normal and atherosclerotic aortaEur Heart J.(1990 Aug)
183.^Ou HC, Lee WJ, Lee IT, Chiu TH, Tsai KL, Lin CY, Sheu WHGinkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cellsJ Appl Physiol.(2009 May)
185.^Ou HC, Hsieh YL, Yang NC, Tsai KL, Chen KL, Tsai CS, Chen IJ, Wu BT, Lee SDGinkgo biloba extract attenuates oxLDL-induced endothelial dysfunction via an AMPK-dependent mechanismJ Appl Physiol.(2013 Jan 15)
186.^Pierre SV, Lesnik P, Moreau M, Bonello L, Droy-Lefaix MT, Sennoune S, Duran MJ, Pressley TA, Sampol J, Chapman J, Maixent JMThe standardized Ginkgo biloba extract Egb-761 protects vascular endothelium exposed to oxidized low density lipoproteinsCell Mol Biol (Noisy-le-grand).(2008 Oct 26)
188.^de Winther MP, Hofker MHScavenging new insights into atherogenesisJ Clin Invest.(2000 Apr)
192.^Van Eck M, Pennings M, Hoekstra M, Out R, Van Berkel TJScavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosisCurr Opin Lipidol.(2005 Jun)
193.^Sevov M, Elfineh L, Cavelier LBResveratrol regulates the expression of LXR-alpha in human macrophagesBiochem Biophys Res Commun.(2006 Sep 29)
195.^Tsai JY, Su KH, Shyue SK, Kou YR, Yu YB, Hsiao SH, Chiang AN, Wu YL, Ching LC, Lee TSEGb761 ameliorates the formation of foam cells by regulating the expression of SR-A and ABCA1: role of haem oxygenase-1Cardiovasc Res.(2010 Dec 1)
196.^Wei JM, Wang X, Gong H, Shi YJ, Zou YGinkgo suppresses atherosclerosis through downregulating the expression of connexin 43 in rabbitsArch Med Sci.(2013 Apr 20)
197.^Blackburn JP, Peters NS, Yeh HI, Rothery S, Green CR, Severs NJUpregulation of connexin43 gap junctions during early stages of human coronary atherosclerosisArterioscler Thromb Vasc Biol.(1995 Aug)
198.^Kwak BR, Veillard N, Pelli G, Mulhaupt F, James RW, Chanson M, Mach FReduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient miceCirculation.(2003 Feb 25)
199.^Burnier L, Fontana P, Angelillo-Scherrer A, Kwak BRIntercellular communication in atherosclerosisPhysiology (Bethesda).(2009 Feb)
200.^Rodríguez M, Ringstad L, Schäfer P, Just S, Hofer HW, Malmsten M, Siegel GReduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patientsAtherosclerosis.(2007 Jun)
201.^Klebanoff SJMyeloperoxidase: friend and foeJ Leukoc Biol.(2005 May)
202.^Hansson GKInflammation, atherosclerosis, and coronary artery diseaseN Engl J Med.(2005 Apr 21)
204.^Kubota Y, Tanaka N, Kagota S, Nakamura K, Kunitomo M, Umegaki K, Shinozuka KEffects of Ginkgo biloba extract feeding on salt-induced hypertensive Dahl ratsBiol Pharm Bull.(2006 Feb)
205.^Kubota Y, Tanaka N, Kagota S, Nakamura K, Kunitomo M, Umegaki K, Shinozuka KEffects of Ginkgo biloba extract on blood pressure and vascular endothelial response by acetylcholine in spontaneously hypertensive ratsJ Pharm Pharmacol.(2006 Feb)
209.^Maxwell S, Greig LAnti-oxidants-- a protective role in cardiovascular diseaseExpert Opin Pharmacother.(2001 Nov)
210.^Umegaki K, Shinozuka K, Watarai K, Takenaka H, Yoshimura M, Daohua P, Esashi TGinkgo biloba extract attenuates the development of hypertension in deoxycorticosterone acetate-salt hypertensive ratsClin Exp Pharmacol Physiol.(2000 Apr)
211.^McKenna DJ, Jones K, Hughes KEfficacy, safety, and use of ginkgo biloba in clinical and preclinical applicationsAltern Ther Health Med.(2001 Sep-Oct)
212.^Auguet M, Delaflotte S, Hellegouarch A, Clostre FPharmacological bases of the vascular impact of Ginkgo biloba extractPresse Med.(1986 Sep 25)
213.^Förstermann U, Münzel TEndothelial nitric oxide synthase in vascular disease: from marvel to menaceCirculation.(2006 Apr 4)
214.^Koltermann A, Hartkorn A, Koch E, Fürst R, Vollmar AM, Zahler SGinkgo biloba extract EGb 761 increases endothelial nitric oxide production in vitro and in vivoCell Mol Life Sci.(2007 Jul)
215.^Keheyan G, Dunn LA, Hall WLAcute effects of Ginkgo biloba extract on vascular function and blood pressurePlant Foods Hum Nutr.(2011 Sep)
217.^Mehlsen J, Drabaek H, Wiinberg N, Winther KEffects of a Ginkgo biloba extract on forearm haemodynamics in healthy volunteersClin Physiol Funct Imaging.(2002 Nov)
222.^Brinkley TE, Lovato JF, Arnold AM, Furberg CD, Kuller LH, Burke GL, Nahin RL, Lopez OL, Yasar S, Williamson JD; Ginkgo Evaluation of Memory (GEM) Study InvestigatorsEffect of Ginkgo biloba on blood pressure and incidence of hypertension in elderly men and womenAm J Hypertens.(2010 May)
223.^Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working GroupInter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)J Vasc Surg.(2007 Jan)
224.^Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease FoundationACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease FoundationCirculation.(2006 Mar 21)
225.^Farah BQ, Dos Anjos Souza Barbosa JP, Cucato GG, da Rocha Chehuen M, Gobbo LA, Wolosker N, de Moraes Forjaz CL, Dias RMPredictors of walking capacity in peripheral arterial disease patientsClinics (Sao Paulo).(2013 Apr)
229.^Thomson GJ, Vohra RK, Carr MH, Walker MGA clinical trial of Gingkco Biloba Extract in patients with intermittent claudicationInt Angiol.(1990 Apr-Jun)
230.^Gardner CD, Taylor-Piliae RE, Kiazand A, Nicholus J, Rigby AJ, Farquhar JWEffect of Ginkgo biloba (EGb 761) on treadmill walking time among adults with peripheral artery disease: a randomized clinical trialJ Cardiopulm Rehabil Prev.(2008 Jul-Aug)
232.^Moraga FA, Flores A, Serra J, Esnaola C, Barriento CGinkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in northern ChileWilderness Environ Med.(2007 Winter)
233.^Leadbetter G, Keyes LE, Maakestad KM, Olson S, Tissot van Patot MC, Hackett PHGinkgo biloba does--and does not--prevent acute mountain sicknessWilderness Environ Med.(2009 Spring)
234.^Roncin JP, Schwartz F, D'Arbigny PEGb 761 in control of acute mountain sickness and vascular reactivity to cold exposureAviat Space Environ Med.(1996 May)
237.^Chow T, Browne V, Heileson HL, Wallace D, Anholm J, Green SMGinkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trialArch Intern Med.(2005 Feb 14)
240.^Liu XP, Goldring CE, Copple IM, Wang HY, Wei W, Kitteringham NR, Park BKExtract of Ginkgo biloba induces phase 2 genes through Keap1-Nrf2-ARE signaling pathwayLife Sci.(2007 Apr 3)
241.^Chou PB, Morse CAUnderstanding premenstrual syndrome from a Chinese medicine perspectiveJ Altern Complement Med.(2005 Apr)
242.^Chou PB, Morse CA, Xu HA controlled trial of Chinese herbal medicine for premenstrual syndromeJ Psychosom Obstet Gynaecol.(2008 Sep)
244.^Ozgoli G, Selselei EA, Mojab F, Majd HAA randomized, placebo-controlled trial of Ginkgo biloba L. in treatment of premenstrual syndromeJ Altern Complement Med.(2009 Aug)
245.^Cohen AJ, Bartlik BGinkgo biloba for antidepressant-induced sexual dysfunctionJ Sex Marital Ther.(1998 Apr-Jun)
248.^Sintchak G, Geer JHA vaginal plethysmograph systemPsychophysiology.(1975 Jan)
255.^Burnett AL, Calvin DC, Silver RI, Peppas DS, Docimo SGImmunohistochemical description of nitric oxide synthase isoforms in human clitorisJ Urol.(1997 Jul)
256.^Kobayashi N, Suzuki R, Koide C, Suzuki T, Matsuda H, Kubo MEffect of leaves of Ginkgo biloba on hair regrowth in C3H strain miceYakugaku Zasshi.(1993 Oct)
258.^Chuarienthong P, Lourith N, Leelapornpisid PClinical efficacy comparison of anti-wrinkle cosmetics containing herbal flavonoidsInt J Cosmet Sci.(2010 Apr)
259.^Ernst E, Stevinson CGinkgo biloba for tinnitus: a reviewClin Otolaryngol Allied Sci.(1999 Jun)
260.^Han SS, Nam EC, Won JY, Lee KU, Chun W, Choi HK, Levine RAClonazepam quiets tinnitus: a randomised crossover study with Ginkgo bilobaJ Neurol Neurosurg Psychiatry.(2012 Aug)
262.^Hilton MP, Zimmermann EF, Hunt WTGinkgo biloba for tinnitusCochrane Database Syst Rev.(2013 Mar 28)
263.^Levene RZLow tension glaucoma: a critical review and new materialSurv Ophthalmol.(1980 May-Jun)
264.^Park JW, Kwon HJ, Chung WS, Kim CY, Seong GJShort-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucomaKorean J Ophthalmol.(2011 Oct)
265.^Quaranta L, Bettelli S, Uva MG, Semeraro F, Turano R, Gandolfo EEffect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucomaOphthalmology.(2003 Feb)
267.^Chung HS, Harris A, Kristinsson JK, Ciulla TA, Kagemann C, Ritch RGinkgo biloba extract increases ocular blood flow velocityJ Ocul Pharmacol Ther.(1999 Jun)
268.^Wimpissinger B, Berisha F, Garhoefer G, Polak K, Schmetterer LInfluence of Ginkgo biloba on ocular blood flowActa Ophthalmol Scand.(2007 Jun)
269.^Russo V, Stella A, Appezzati L, Barone A, Stagni E, Roszkowska A, Delle Noci NClinical efficacy of a Ginkgo biloba extract in the topical treatment of allergic conjunctivitisEur J Ophthalmol.(2009 May-Jun)
271.^Attia A, Rapp SR, Case LD, D'Agostino R, Lesser G, Naughton M, McMullen K, Rosdhal R, Shaw EGPhase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and moodJ Neurooncol.(2012 Sep)
272.^Biggs ML, Sorkin BC, Nahin RL, Kuller LH, Fitzpatrick ALGinkgo biloba and risk of cancer: secondary analysis of the Ginkgo Evaluation of Memory (GEM) StudyPharmacoepidemiol Drug Saf.(2010 Jul)
273.^Ioannidis JPWhy most published research findings are falsePLoS Med.(2005 Aug)
274.^Porter JM, Rivers SP, Anderson CJ, Baur GMEvaluation and management of patients with Raynaud's syndromeAm J Surg.(1981 Aug)
276.^Thompson AE, Pope JECalcium channel blockers for primary Raynaud's phenomenon: a meta-analysisRheumatology (Oxford).(2005 Feb)
279.^Whitton ME, Ashcroft DM, Barrett CW, Gonzalez UInterventions for vitiligoCochrane Database Syst Rev.(2006 Jan 25)
280.^Porter J, Beuf AH, Lerner A, Nordlund JResponse to cosmetic disfigurement: patients with vitiligoCutis.(1987 Jun)
281.^Ongenae K, Beelaert L, van Geel N, Naeyaert JMPsychosocial effects of vitiligoJ Eur Acad Dermatol Venereol.(2006 Jan)
282.^Forschner T, Buchholtz S, Stockfleth ECurrent state of vitiligo therapy--evidence-based analysis of the literatureJ Dtsch Dermatol Ges.(2007 Jun)
283.^Szczurko O, Shear N, Taddio A, Boon HGinkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trialBMC Complement Altern Med.(2011 Mar 15)
284.^Parsad D, Pandhi R, Juneja AEffectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligoClin Exp Dermatol.(2003 May)
285.^Kennedy DO, Haskell CF, Mauri PL, Scholey ABAcute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserineHum Psychopharmacol.(2007 Jun)
288.^Wesnes KA, Ward T, McGinty A, Petrini OThe memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteersPsychopharmacology (Berl).(2000 Nov)
291.^Wesnes KA, Faleni RA, Hefting NR, Hoogsteen G, Houben JJ, Jenkins E, Jonkman JH, Leonard J, Petrini O, van Lier JJThe cognitive, subjective, and physical effects of a ginkgo biloba/panax ginseng combination in healthy volunteers with neurasthenic complaintsPsychopharmacol Bull.(1997)
294.^Nathan PJ, Tanner S, Lloyd J, Harrison B, Curran L, Oliver C, Stough CEffects of a combined extract of Ginkgo biloba and Bacopa monniera on cognitive function in healthy humansHum Psychopharmacol.(2004 Mar)
296.^Miller LG, Freeman BPossible subdural hematoma associated with Ginkgo bilobaJ Herb Pharmacother.(2002)